The PennZone

  • Home
  • Non-profit
  • Business
  • Education
  • Construction
  • Health
  • Technology
  • Entertainment
  • Software

MYONEX ANNOUNCES ACQUISITION OF SAVEWAY COMPOUNDING PHARMACY TO EXPAND ITS CLINICAL TRIAL SERVICES ACROSS THE US USA - English USA - español USA - English
The PennZone/10266682

Trending...
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • Philadelphia's First Ginger Store Honored With City Citation for Nine Years of Health and Wellness
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
HORSHAM, Pa., April 9, 2024 ~ Myonex, a leading global clinical trial supply company, has recently announced the completion of its acquisition of SaveWay Compounding Pharmacy in Newark, Delaware. The pharmacy will now operate as SaveWay Compounding Pharmacy, a Myonex company.

This strategic move by Myonex is part of their ongoing efforts to support clinical trial sponsors' trial designs with direct-to-patient (DTP) and home healthcare provider (HHP) capabilities. With this acquisition, Myonex aims to provide wider patient access across the entire United States and support patients in obtaining the necessary trial medication and equipment.

According to James Lovett, Chief Executive Officer at Myonex, "SaveWay's pharmacy capabilities complement and extend our existing clinical supplies solutions within the US. SaveWay will provide additional access for drug sourcing and direct-to-patient options across all 50 states for our clinical packaging and labeling and ancillary supply services." This will also complement Myonex's market-leading CTRx™ to offer a full suite of prescription-based supply options for both investigational medicinal product (IMP) and commercial drug access throughout the US. These added capabilities will enable Myonex to better serve their clients' needs and facilitate decentralized clinical trials (DCT) and hybrid studies.

More on The PennZone
  • The Personal Development Industry Has a Blind Spot Says Global Personal Success Guru Omar L. Harris
  • Kevin "Mr. Wonderful" O'Leary Begins New Universal Coin & Bullion Promotion of Gold and Silver
  • Flamingo Compliance Launches Schengen Area Trip Planning Tools as New Digital Border Controls Take Effect
  • HHS Announces Major Push to Address Psychiatric Drug Risks: CCHR Applauds Focus on Informed Consent and Safe Tapering
  • PhaseZero Launches Eight AI Agents for Manufacturers and Distributors - Connecting Sales, Support, and Operations Teams Across Full Commerce Journey

The acquisition also presents an opportunity for SaveWay to expand into the realm of clinical trials and accelerate the growth of their direct-to-patient services. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed excitement about this partnership: "We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today's trends in clinical trials."

This recent acquisition announcement comes on the heels of another significant acquisition by Myonex – that of Creapharm – further solidifying their commitment to providing faster, more flexible, and reliable services to their clients while improving the clinical trial patient experience. With these acquisitions, Myonex now boasts one of the most diverse clinical trial supply service offerings globally.

Myonex was exclusively advised by Crosstree as its financial advisor and Troutman Pepper as its legal advisor in this acquisition of SaveWay. This partnership is expected to bring about significant growth and success for both companies in the clinical trial supply industry.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • ThoroughCare Expands Remote Patient Monitoring with Withings Integration
  • Wellsboro Earns Gold Bird Town Certification, Highlighting Conservation Leadership
  • XMax Inc. (N A S D A Q) Accelerates AI Expansion With $4.8 Million Contracted Revenue, $30+ Million Enterprise Pipeline and Strategic SpaceX Exposure
  • Lnk.Bio Becomes the First Link-in-Bio Service Fully Manageable from Inside ChatGPT
  • Did Drake Just Find His Next Signee? Peoria Rapper Rhymi Gifts "ICEMANDRAKE" Domains, Drops Debut Album Same Day
  • Andrew Tate Says Los Angeles Is "Where I Belong" as He Hints at USA Move
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • VeneerVibe Releases 2026 Snap-On Veneers Market Report
  • David Cavanagh Launches AI SEO Company For ChatGPT And AI Search Visibility
  • Matthew Cossolotto Spotlights Make a Promise Day 2026 Events, Including Official Launch of Harness Your PromisePower and Issuing a "Peace Promise"
  • Landmark Expands Services to Include Specialized Glass and Glazing Solutions Across Los Angeles
  • As Pentagon Releases Ufo Files, Debut Ya Novel Predicted It All
  • RAATV Premieres Original Reality Series "The Access Index: Jackson" June, 19
  • Connecticut Resident Develops Patent-Pending Concept Exploring a New Approach to GPS Navigation
  • JP Events Azerbaijan to Host 2nd Women in Motorsport Event During the Azerbaijan Grand Prix Week
  • MMA Platform Makes History, Pays Jamey-Lyn Horth After Fans Vote on UFC Winnipeg Robbery
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • Premiere Venue Group Announces $25,000 Sponsorship to Support Ann's Heart Programs and Events
  • L2 Aviation Awarded IDIQ Contract by the U.S. Army for M1A2 Abrams Tank

Popular on PennZone

  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph - 128
  • Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
  • Eastern Adjustment Group, LLP Provides Property Loss Advocacy and Claim Support
  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • A Powerful Beginning Inside One of Philadelphia's Most Inspiring Early Childhood Education Centers
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
  • Strategic Talent Associates Launches THE ALIGNED RESET™

Similar on PennZone

  • The Personal Development Industry Has a Blind Spot Says Global Personal Success Guru Omar L. Harris
  • @tickerbitcoinbb and @girl_still_cute Announce the Arrival of SPROTO AEON BABY 1.0 – A New Chapter for the HarryPotterObamaSonic10Inu Universe
  • Slotozilla Expands Bonus Portfolio and Affiliate Reach Following iGB Barcelona 2026
  • XMax Inc. (N A S D A Q) Accelerates AI Expansion With $4.8 Million Contracted Revenue, $30+ Million Enterprise Pipeline and Strategic SpaceX Exposure
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • David Cavanagh Launches AI SEO Company For ChatGPT And AI Search Visibility
  • Matthew Cossolotto Spotlights Make a Promise Day 2026 Events, Including Official Launch of Harness Your PromisePower and Issuing a "Peace Promise"
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • KDG Redefines Enterprise Software Development with AI-Assisted and Agentic Delivery Model
  • Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us